Skip to main content

Table 4 Biomarker inhibition in paired tumor biopsies of individual patients treated with LJM716 40 mg/kg QW

From: A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Patient biopsy Best response t-HER3 p-HER3 HER3 ratio (P/T) t-AKT p-AKT AKT ratio (P/T)
1 PD −86% ↑ 81% ↓ 90% ↓ 7% ↓ 84% ↓ 83% ↓
2 SD ND −157% ↑ ND −249% ↑ −84% ↑ 47% ↓
3 PD ND 63% ↓ ND ND ND ND
4 SD 25% ↓ ND ND −33% ↑ 0% 25% ↓
5 SD 72% ↓ 82% ↓ 34% ↓ 70% ↓ ND ND
Median   25% 72% ↓ 62% ↓ −13% ↑ 0% 47% ↓
  1. Percentages represent changes in the post-baseline sample against the baseline value
  2. Positive and negative values represent biomarker inhibition (↓) and stimulation (↑), respectively
  3. HER3 human epidermal growth factor receptor 3, ND not determined, PD progressive disease, p-AKT phosphor-AKT, p-HER3 phospho-HER3, Q2W once every two weeks, QW once weekly, SD stable disease, t-AKT total AKT, t-HER3 total HER3